Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures

Press

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference

By Biomarck

Read More

Biomarck Announces, Phase 2a Clinical Trial Results of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)

By Biomarck

Read More

Biomarck Pharmaceuticals to Participate in 38th Annual J.P. Morgan
Healthcare Conference on Thursday, January 16th, 2020

By Biomarck

Read more

After daughter’s cancer death, family supports experimental treatment developed in Triangle

By Maggie Newland

Watch Video

Biomarck announces statistically significant results from the Phase 2 controlled clinical study in non small cell lung cancer (NSCLC)

BioMarck

Read Article

Biomarck Announces the start of a Phase 2 Clinical Trial of BIO-11006 for Non-
Small Cell Lung Cancer (NSCLC)

BioMarck

Read Article

Biomarck Announces First Patients Treated in Phase 2 Clinical Trial of BIO-
11006 for Acute Respiratory Distress Syndrome (ARDS)

BioMarck

Read Article

Groundbreaking Cancer Research, Decades in the Making

By Jordan Bartel/NC State Veterinary Medicine

Watch Video

South Florida Connection To Possible Cancer Miracle Drug

CBS Miami’s Gary Nelson reports from Hialeah.

Watch Video

After daughter’s cancer death, family supports experimental treatment developed in Triangle

By Maggie Newland

Watch Video